IP Library Granted Patent US 8,507,471
Granted Patent B2
US 8,507,471 · App. 12/663,490 · Granted Aug 13, 2013

Biphenylcarboxamide derivatives as hedgehod pathway modulators

Inventors: Christine Dierks (Freiburg, DE); Markus Warmuth (Natick, MA); Xu Wu (San Diego, CA)
Assignee: IRM LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,507,471
App. No.
12/663,490
Granted
Aug 13, 2013
Kind
B2
Abstract

The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.

Claims (11)

1. A method of treating a hematological cancer comprising administering to a patient in need thereof a therapeutically effective amount of N-(6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4′-(trifluoromethoxy)biphenyl-3-carboxamide as shown by the below structure

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the cancer is plasma cell neoplasm.

3. The method of claim 1 , wherein the cancer is leukemia.

4. The method of claim 3 , wherein the cancer is childhood leukemia.

5. The method of claim 3 , wherein the cancer is chronic lymphocytic leukemia, acute leukemia or chronic leukemia.

6. The method of claim 1 , wherein the cancer is lymphoma.

7. The method of claim 6 , wherein the cancer is malignant lymphoma.

8. The method of claim 6 , wherein the cancer is Hodgkin's lymphoma.

9. The method of claim 6 , wherein the cancer is non-Hodgkin's lymphoma, stroma dependent lymphoma, lymphomas of lymphocytic and cutaneous origin, B-cell lymphoma, plasmoblastoma, or plasmacytoma.

10. The method of claim 1 , wherein the cancer is multiple myeloma.

Assignments (5)
MERGER Recorded Feb 15, 2023
From: SUN PHARMA GLOBAL FZE
To: SUN PHARMACEUTICAL INDUSTRIES LIMITED
Reel/Frame 062709/0922 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2017
From: NOVARTIS AG
To: SUN PHARMA GLOBAL FZE
Reel/Frame 041537/0215 →
MERGER AND CHANGE OF NAME Recorded Jan 27, 2016
From: IRM LLC; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.
To: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.
Reel/Frame 037599/0484 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2015
From: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.
To: NOVARTIS AG
Reel/Frame 035635/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2013
From: DIERKS, CHRISTINE; WARMUTH, MARKUS; WU, XU
To: IRM LLC
Reel/Frame 029606/0644 →
Continuity (2)
Provisional Application 60942654 · Jun 7, 2007
Related Publication 20100197659A1 · Aug 5, 2010